dostęp otwarty

Tom 3, Nr 1-2 (2017)
Opisy przypadków
Opublikowany online: 2017-12-31
Pobierz cytowanie

Artykuł widmo - zdeponowany dla zrobienia bibliografii do KP, 6.10.2017, M. Kunicki

Mateusz Kunicki
Nadciśnienie Tętnicze w Praktyce 2017;3(1-2):1-2.

dostęp otwarty

Tom 3, Nr 1-2 (2017)
Opisy przypadków
Opublikowany online: 2017-12-31

Streszczenie

Artykuł widmo - zdeponowany dla zrobienia bibliografii do KP, 6.10.2017, M. Kunicki.

Streszczenie

Artykuł widmo - zdeponowany dla zrobienia bibliografii do KP, 6.10.2017, M. Kunicki.

Pobierz cytowanie

Słowa kluczowe

vm

Informacje o artykule
Tytuł

Artykuł widmo - zdeponowany dla zrobienia bibliografii do KP, 6.10.2017, M. Kunicki

Czasopismo

Nadciśnienie Tętnicze w Praktyce

Numer

Tom 3, Nr 1-2 (2017)

Strony

1-2

Data publikacji on-line

2017-12-31

Rekord bibliograficzny

Nadciśnienie Tętnicze w Praktyce 2017;3(1-2):1-2.

Słowa kluczowe

vm

Autorzy

Mateusz Kunicki

Referencje (193)
  1. de Weerd M, Greving JP, de Jong AWF, et al. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis. Stroke. 2009; 40(4): 1105–1113.
  2. Razzouk L, Rockman CB, Patel MR, et al. Co-existence of vascular disease in different arterial beds: Peripheral artery disease and carotid artery stenosis--Data from Life Line Screening(®). Atherosclerosis. 2015; 241(2): 687–691.
  3. Osborn LA, Vernon SM, Reynolds B, et al. Screening for subclavian artery stenosis in patients who are candidates for coronary bypass surgery. Catheter Cardiovasc Interv. 2002; 56(2): 162–165.
  4. Shadman R, Criqui MH, Bundens WP, et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol. 2004; 44(3): 618–623.
  5. Hansen KJ, Wilson DB, Craven TE, et al. Mesenteric artery disease in the elderly. J Vasc Surg. 2004; 40(1): 45–52.
  6. Bageacu S, Cerisier A, Isaaz K, et al. Incidental visceral and renal artery stenosis in patients undergoing coronary angiography. Eur J Vasc Endovasc Surg. 2011; 41(3): 385–390.
  7. Valentine RJ, Martin JD, Myers SI, et al. Asymptomatic celiac and superior mesenteric artery stenoses are more prevalent among patients with unsuspected renal artery stenoses. J Vasc Surg. 1991; 14(2): 195–199.
  8. Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002; 36(3): 443–451.
  9. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901): 1329–1340.
  10. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004; 172(1): 95–105.
  11. Grøndal N, Søgaard R, Lindholt JS. Baseline prevalence of abdominal aortic aneurysm, peripheral arterial disease and hypertension in men aged 65-74 years from a population screening study (VIVA trial). Br J Surg. 2015; 102(8): 902–906.
  12. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007; 45(6): 1185–1191.
  13. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S: S5–67.
  14. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116(9): 1509–1526.
  15. Hooi JD, Kester AD, Stoffers HE, et al. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol. 2001; 153(7): 666–672.
  16. Sampson UKA, Fowkes FG, McDermott MM, et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Glob Heart. 2014; 9(1): 145–158.e21.
  17. Högberg D, Kragsterman B, Björck M, et al. Carotid artery atherosclerosis among 65-year-old Swedish men - a population-based screening study. Eur J Vasc Endovasc Surg. 2014; 48(1): 5–10.
  18. de Weerd M, Greving JP, Hedblad Bo, et al. Prediction of asymptomatic carotid artery stenosis in the general population: identification of high-risk groups. Stroke. 2014; 45(8): 2366–2371.
  19. West HW, Juonala M, Gall SL, et al. Exposure to parental smoking in childhood is associated with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation. 2015; 131(14): 1239–1246.
  20. Herder M, Johnsen SH, Arntzen KA, et al. Risk factors for progression of carotid intima-media thickness and total plaque area: a 13-year follow-up study: the Tromsø Study. Stroke. 2012; 43(7): 1818–1823.
  21. Redgrave JNE, Lovett JK, Rothwell PM. Histological features of symptomatic carotid plaques in relation to age and smoking: the oxford plaque study. Stroke. 2010; 41(10): 2288–2294.
  22. Tobe SW, Burgess E, Lebel M. Atherosclerotic renovascular disease. Can J Cardiol. 2006; 22(7): 623–628.
  23. Slovut DP, Olin JW, Slovut DP, et al. Fibromuscular dysplasia. N Engl J Med. 2004; 350(18): 1862–1871.
  24. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012; 308(16): 1660–1667.
  25. Bots ML, Breslau PJ, Briët E, et al. Cardiovascular determinants of carotid artery disease. The Rotterdam Elderly Study. Hypertension. 1992; 19(6 Pt 2): 717–720.
  26. Mathiesen E, Joakimsen O, Bønaa K. Prevalence of and Risk Factors Associated with Carotid Artery Stenosis: The Tromsø Study. Cerebrovasc Dis. 2001; 12(1): 44–51.
  27. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke. 1992; 23(12): 1752–1760.
  28. Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis. 2009; 52(3): 184–195.
  29. Garg PK, Biggs ML, Carnethon M, et al. Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study. Hypertension. 2014; 63(2): 413–419.
  30. Emdin CA, Anderson SG, Callender T, et al. Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. BMJ. 2015; 351: h4865.
  31. Howard DP, Banerjee A, Fairhead JF, et al. Population-based study of incidence, risk factors, outcome, and prognosis of is- chemic peripheral arterial events: implications for prevention. Circulation. 2015; 132(19): 1805–1815.
  32. Allison MA, Criqui MH, McClelland RL, et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006; 48(6): 1190–1197.
  33. Meijer WT, Grobbee DE, Hunink MG, et al. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000; 160(19): 2934–2938.
  34. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993; 88(3): 837–845.
  35. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285(19): 2481–2485.
  36. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002; 143(6): 961–965.
  37. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006; 113(22): 2623–2629.
  38. Laschkolnig A, Kollerits B, Lamina C, et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res. 2014; 103(1): 28–36.
  39. Scholtes VPW, Peeters W, van Lammeren GW, et al. Type 2 diabetes is not associated with an altered plaque phenotype among patients undergoing carotid revascularization. A histological analysis of 1455 carotid plaques. Atherosclerosis. 2014; 235(2): 418–423.
  40. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001; 24(8): 1433–1437.
  41. Stone PA, Yacoub M. Inflammatory biomarkers in peripheral arterial disease. Semin Vasc Surg. 2014; 27(3-4): 148–151.
  42. Tzoulaki I, Murray GD, Lee AJ, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007; 28(3): 354–362.
  43. Chuang YW, Yu MC, Lin CL, et al. Risk of peripheral arterial occlusive disease in patients with rheumatoid arthritis. A nationwide population-based cohort study. Thromb Haemost. 2016; 115(2): 439–445.
  44. Peeters Weem SMO, van Haelst STW, den Ruijter HM, et al. Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. Eur J Vasc Endovasc Surg. 2016; 52(2): 253–262.
  45. Mousa AY, Broce M, Campbell J, et al. Clopidogrel use before renal artery angioplasty with/without stent placement resulted in tertiary procedure risk reduction. J Vasc Surg. 2012; 56(2): 416–423.
  46. Sacco RL, Kasner SE, Broderick JP, et al. American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7): 2064–2089.
  47. Rerkasem K, Bond R, Rothwell PM. Local versus general anaesthesia for carotid endarterectomy. Cochrane Database Syst Rev. 2004(2): CD000126.
  48. Vaniyapong T, Chongruksut W, Rerkasem K. Local versus general anaesthesia for carotid endarterectomy. Cochrane Database Syst Rev. 2013(12): CD000126.
  49. Cao P, De Rango P, Zannetti S. Eversion vs conventional carotid endarterectomy: a systematic review. Eur J Vasc Endovasc Surg. 2002; 23(3): 195–201.
  50. Rerkasem K, Rothwell PM. Systematic Review of Randomized Controlled Trials of Patch Angioplasty Versus Primary Closure and Different Types of Patch Materials During Carotid Endarterectomy. Asian J Surg. 2011; 34(1): 32–40.
  51. Chongruksut W, Vaniyapong T, Rerkasem K. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). Cochrane Database Syst Rev. 2014(6): CD000190.
  52. Doig D, Turner EL, Dobson J, et al. ICSS Investigators. Incidence, impact, and predictors of cranial nerve palsy and haematoma following carotid endarterectomy in the international carotid stenting study. Eur J Vasc Endovasc Surg. 2014; 48(5): 498–504.
  53. Bond R, Narayan SK, Rothwell PM, et al. European Carotid Surgery Trialists' Collaborative Group. Clinical and radiographic risk factors for operative stroke and death in the European carotid surgery trial. Eur J Vasc Endovasc Surg. 2002; 23(2): 108–116.
  54. Ferguson GG, Eliasziw M, Barr HW, et al. The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients. Stroke. 1999; 30(9): 1751–1758.
  55. Touzé E, Trinquart L, Felgueiras R, et al. Carotid Stenting Trialists’ Collaboration. A clinical rule (sex, contralateral occlusion, age, and restenosis) to select patients for stenting versus carotid endarterectomy: systematic review of observational studies with validation in randomized trials. Stroke. 2013; 44(12): 3394–3400.
  56. Holt PJE, Poloniecki JD, Loftus IM, et al. Meta-analysis and systematic review of the relationship between hospital volume and outcome following carotid endarterectomy. Eur J Vasc Endovasc Surg. 2007; 33(6): 645–651.
  57. AbuRahma AF, Stone PA, Srivastava M, et al. The effect of surgeon's specialty and volume on the perioperative outcome of carotid endarterectomy. J Vasc Surg. 2013; 58(3): 666–672.
  58. Macdonald S, Lee R, Williams R, et al. Delphi Carotid Stenting Consensus Panel. Towards safer carotid artery stenting: a scoring system for anatomic suitability. Stroke. 2009; 40(5): 1698–1703.
  59. Ederle J, Dobson J, Featherstone RL, et al. International Carotid Stenting Study investigators. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet. 2010; 375(9719): 985–997.
  60. Mas JL, Chatellier G, Beyssen B, et al. EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006; 355(16): 1660–1671.
  61. Moore WS, Popma JJ, Roubin GS, et al. CREST Investigators. Carotid angiographic characteristics in the CREST trial were major contributors to periprocedural stroke and death differences between carotid artery stenting and carotid endarterectomy. J Vasc Surg. 2016; 63(4): 851–7, 858.e1.
  62. Ringleb PA, Allenberg J, Brückmann H, et al. SPACE Collaborative Group. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet. 2006; 368(9543): 1239–1247.
  63. Silver FL, Mackey A, Clark WM, et al. CREST Investigators. Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke. 2011; 42(3): 675–680.
  64. Gray WA, Rosenfield KA, Jaff MR, et al. CAPTURE 2 Investigators and Executive Committee. Influence of site and operator characteristics on carotid artery stent outcomes: analysis of the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) clinical study. JACC Cardiovasc Interv. 2011; 4(2): 235–246.
  65. Nallamothu BK, Gurm HS, Ting HH, et al. Operator experience and carotid stenting outcomes in Medicare beneficiaries. JAMA. 2011; 306(12): 1338–1343.
  66. Roffi M, Sievert H, Gray WA, et al. Carotid artery stenting versus surgery: adequate comparisons? Lancet Neurol. 2010; 9(4): 339–41; author reply 341.
  67. Calvet D, Mas JL, Algra A, et al. Carotid Stenting Trialists’ Collaboration. Carotid stenting: is there an operator effect? A pooled analysis from the carotid stenting trialists' collaboration. Stroke. 2014; 45(2): 527–532.
  68. Dua A, Romanelli M, Upchurch GR, et al. Predictors of poor outcome after carotid intervention. J Vasc Surg. 2016; 64(3): 663–670.
  69. Kakkos SK, Sabetai M, Tegos T, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Silent embolic infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events in patients with asymptomatic internal carotid artery stenosis. J Vasc Surg. 2009; 49(4): 902–909.
  70. Kakkos SK, Nicolaides AN, Charalambous I, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg. 2014; 59(4): 956–967.e1.
  71. Hirt LS. Progression rate and ipsilateral neurological events in asymptomatic carotid stenosis. Stroke. 2014; 45(3): 702–706.
  72. Nicolaides AN, Kakkos SK, Kyriacou E, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. J Vasc Surg. 2010; 52(6): 1486–1496.e1.
  73. Kakkos SK, Griffin MB, Nicolaides AN, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. The size of juxtaluminal hypoechoic area in ultrasound images of asymptomatic carotid plaques predicts the occurrence of stroke. J Vasc Surg. 2013; 57(3): 609–618.e1; discussion 617.
  74. Gupta A, Baradaran H, Schweitzer AD, et al. Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke. 2013; 44(11): 3071–3077.
  75. King A, Serena J, Bornstein NM, et al. ACES Investigators. Does impaired cerebrovascular reactivity predict stroke risk in asymptomatic carotid stenosis? A prospective substudy of the asymptomatic carotid emboli study. Stroke. 2011; 42(6): 1550–1555.
  76. Gupta A, Kesavabhotla K, Baradaran H, et al. Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic review and meta-analysis. Stroke. 2015; 46(1): 91–97.
  77. Markus HS, King A, Shipley M, et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. Lancet Neurol. 2010; 9(7): 663–671.
  78. Topakian R, King A, Kwon SU, et al. ACES Investigators. Ultrasonic plaque echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. Neurology. 2011; 77(8): 751–758.
  79. Nicolaides AN, Kakkos SK, Griffin M, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Eur J Vasc Endovasc Surg. 2005; 30(3): 275–284.
  80. Brooks WH, McClure RR, Jones MR, et al. Carotid angio- plasty and stenting versus carotid endarterectomy for treatment of asymptom- atic carotid stenosis: a randomized trial in a community hospital. Neurosurgery. 2004; 54: 318–324.
  81. Hill MD, Brooks W, Mackey A, et al. CREST Investigators, CREST Investigators. Stroke after carotid stenting and endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Circulation. 2012; 126(25): 3054–3061.
  82. Rosenfield K, Matsumura JS, Chaturvedi S, et al. ACT I Investigators. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. N Engl J Med. 2016; 374(11): 1011–1020.
  83. Eckstein HH, Reiff T, Ringleb P, et al. SPACE 2 Investigators. SPACE-2: A Missed Opportunity to Compare Carotid Endarterectomy, Carotid Stenting, and Best Medical Treatment in Patients with Asymptomatic Carotid Stenoses. Eur J Vasc Endovasc Surg. 2016; 51(6): 761–765.
  84. Mannheim D, Karmeli RA. Prospective randomized trial comparing endarterec- tomy to stenting in severe asymptomatic carotid stenosis. J Cardiovasc Surg. 2016.
  85. Brott TG, Hobson RW, Howard G, et al. CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010; 363(1): 11–23.
  86. Mas JL, Chatellier G, Beyssen B, et al. EVA-3S Investigators. Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S) trial. Stroke. 2004; 35(1): e18–e20.
  87. Howard G, Roubin G, Jansen O, et al. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet. 2016; 387(10025): 1305–1311.
  88. Borhani Haghighi A, Edgell RC, Cruz-Flores S, et al. Vertebral artery origin stenosis and its treatment. J Stroke Cerebrovasc Dis. 2011; 20(4): 369–376.
  89. Mukherjee D, Pineda G. Extracranial vertebral artery intervention. J Interv Cardiol. 2007; 20(6): 409–416.
  90. Gulli G, Marquardt L, Rothwell PM, et al. Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies. Stroke. 2013; 44(3): 598–604.
  91. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012; 379(9819): 905–914.
  92. Labropoulos N, Nandivada P, Bekelis K. Prevalence and impact of the subclavian steal syndrome. Ann Surg. 2010; 252(1): 166–170.
  93. Puttarajappa C, Rajan DS. Images in clinical medicine. Allen's test. N Engl J Med. 2010; 363(14): e20.
  94. Björck M, Koelemay M, Acosta S, et al. Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017; 53(4): 460–510.
  95. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation. 1998; 98(25): 2866–2872.
  96. Jennings CG, Houston JG, Severn A, et al. Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep. 2014; 16(6): 416.
  97. Connolly JO, Higgins RM, Walters HL, et al. Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. QJM. 1994; 87(7): 413–421.
  98. Tafur-Soto JD, White CJ. Renal artery stenosis. Cardiol Clin. 2015; 33(1): 59–73.
  99. Zeller T, Bonvini RF, Sixt S. Color-coded duplex ultrasound for diagnosis of renal artery stenosis and as follow-up examination after revascularization. Catheter Cardiovasc Interv. 2008; 71(7): 995–999.
  100. Boddi M, Natucci F, Ciani E. The internist and the renal resistive index: truths and doubts. Intern Emerg Med. 2015; 10(8): 893–905.
  101. Mulè G, Geraci G, Geraci C, et al. The renal resistive index: is it a misnomer? Intern Emerg Med. 2015; 10(8): 889–891.
  102. Doi Y, Iwashima Y, Yoshihara F, et al. Renal resistive index and cardiovascular and renal outcomes in essential hypertension. Hypertension. 2012; 60(3): 770–777.
  103. Bruno RM, Daghini E, Versari D, et al. Predictive role of renal resistive index for clinical outcome after revascularization in hypertensive patients with atherosclerotic renal artery stenosis: a monocentric observational study. Cardiovasc Ultrasound. 2014; 12: 9.
  104. van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet. 1999; 353(9149): 282–286.
  105. Lederman RJ, Mendelsohn FO, Santos R, et al. Primary renal artery stenting: characteristics and outcomes after 363 procedures. Am Heart J. 2001; 142(2): 314–323.
  106. Misra S, Thatipelli MR, Howe PW, et al. Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery stenoses 4 mm in diameter or smaller. J Vasc Interv Radiol. 2008; 19(6): 833–839.
  107. Zähringer M, Sapoval M, Pattynama PMT, et al. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther. 2007; 14(4): 460–468.
  108. Simone TA, Brooke BS, Goodney PP, et al. Clinical effectiveness of secondary interventions for restenosis after renal artery stenting. J Vasc Surg. 2013; 58(3): 687–694.
  109. Cooper CJ, Haller ST, Colyer W, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation. 2008; 117(21): 2752–2760.
  110. Abela R, Ivanova S, Lidder S, et al. An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc Endovasc Surg. 2009; 38(6): 666–675.
  111. Balzer KM, Pfeiffer T, Rossbach S, et al. Prospective randomized trial of operative vs interventional treatment for renal artery ostial occlusive disease (RAOOD). J Vasc Surg. 2009; 49(3): 667–74; discussion 674.
  112. Duprey A, Chavent B, Meyer-Bisch V, et al. Editor's Choice - Ex vivo Renal Artery Repair with Kidney Autotransplantation for Renal Artery Branch Aneurysms: Long-term Results of Sixty-seven Procedures. Eur J Vasc Endovasc Surg. 2016; 51(6): 872–879.
  113. Ham SW, Weaver FA. Ex vivo renal artery reconstruction for complex renal artery disease. J Vasc Surg. 2014; 60(1): 143–150.
  114. Cambria RP, Brewster DC, L’Italien GJ, et al. The durability of different recon- structive techniques for atherosclerotic renal artery disease. J Vasc Surg. 1994; 20: 76–85.
  115. Novick AC, Ziegelbaum M, Vidt DG, et al. Trends in surgical revascularization for renal artery disease. Ten years' experience. JAMA. 1987; 257(4): 498–501.
  116. Senekowitsch C, Assadian A, Wlk MV, et al. Renal artery surgery in the era of endovascular intervention. Vasa. 2004; 33(4): 226–230.
  117. Barba A, Estallo L, Rodríguez L, et al. Detection of abdominal aortic aneurysm in patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2005; 30(5): 504–508.
  118. Quong WL, Fung ATH, Yu RY, et al. Reassessing the normal toe-brachial index in young healthy adults. J Vasc Surg. 2016; 63(3): 652–656.
  119. Tehan PE, Santos D, Chuter VH. A systematic review of the sensitivity and specificity of the toe-brachial index for detecting peripheral artery disease. Vasc Med. 2016; 21(4): 382–389.
  120. Bagger JP, Helligsoe P, Randsbaek F, et al. Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation. 1997; 95(2): 411–414.
  121. Gargiulo G, Giugliano G, Brevetti L, et al. Use of statins in lower extremity artery disease: a review. BMC Surg. 2012; 12 Suppl 1: S15.
  122. Momsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009; 38(4): 463–474.
  123. Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014(10): CD003748.
  124. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47(2): 330–336.
  125. Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012; 99(12): 1630–1638.
  126. Iida O, Yokoi H, Soga Y, et al. STOP-IC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013; 127(23): 2307–2315.
  127. de Backer T, Stichele RV, Lehert P, et al. Naftidrofuryl for intermit- tent claudication. Cochrane Database Syst Rev. 2008; 2: CD001368.
  128. Boccalon H, Lehert P, Mosnier M. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. Ann Cardiol Angeiol (Paris). 2001; 50(3): 175–182.
  129. Nicolaï S, Kruidenier L, Bendermacher B, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2013; 6: CD006888.
  130. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev. 2013(4): CD000986.
  131. Salhiyyah K, Senanayake E, Abdel-Hadi M, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2012; 1: CD005262.
  132. Sumpio BE, Forsythe RO, Ziegler KR, et al. Clinical implications of the angiosome model in peripheral vascular disease. J Vasc Surg. 2013; 58(3): 814–826.
  133. Bergan JJ, Veith FJ, Bernhard VM, et al. Randomization of autogenous vein and polytetrafluorethylene grafts in femoral-distal reconstruction. Surgery. 1982; 92(6): 921–930.
  134. Biancari F, Juvonen T. Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2014; 47(5): 517–522.
  135. Bosanquet DC, Glasbey J, Williams IM, et al. Systematic Review and Meta-analysis of Direct Versus Indirect Angiosomal Revascularisation of Infrapopliteal Arteries. Eur J Vasc Endovasc Surg. 2014; 48(1): 88–97.
  136. Rashid H, Slim H, Zayed H, et al. The impact of arterial pedal arch quality and angiosome revascularization on foot tissue loss healing and infrapopliteal bypass outcome. J Vasc Surg. 2013; 57(5): 1219–1226.
  137. Ubbink DT, Vermeulen H, Ubbink DT, et al. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2013; 2: CD004001.
  138. Belch J, Hiatt WR, Baumgartner I, et al. TAMARIS Committees and Investigators. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 2011; 377(9781): 1929–1937.
  139. Moazzami K, Moazzami B, Roohi A, et al. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2014(12): CD008347.
  140. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J. 2007; 153(5): 874–880.
  141. Nikol S, Baumgartner I, Van Belle E, et al. TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008; 16(5): 972–978.
  142. Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003; 108(16): 1933–1938.
  143. Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg. 2013; 258(6): 922–929.
  144. Flory CM. Arterial Occlusions Produced by Emboli from Eroded Aortic Atheromatous Plaques. Am J Pathol. 1945; 21(3): 549–565.
  145. HOYE SJ, TEITELBAUM S, GORE I, et al. Atheromatous embolization; a factor in peripheral gangrene. N Engl J Med. 1959; 261(3): 128–131.
  146. Karmody AM, Powers SR, Monaco VJ, et al. “Blue toe” syndrome. An in- dication for limb salvage surgery. Arch Surg. 1976; 111(11): 1263–1268.
  147. Applebaum RM, Kronzon I. Evaluation and management of cholesterol embolization and the blue toe syndrome. Curr Opin Cardiol. 1996; 11(5): 533–542.
  148. Fisher DF, Clagett GP, Brigham RA, et al. Dilemmas in dealing with the blue toe syndrome: aortic versus peripheral source. Am J Surg. 1984; 148(6): 836–839.
  149. Friedman SG, Krishnasastry KV. External iliac ligation and axillary-bifemoral bypass for blue toe syndrome. Surgery. 1994; 115(1): 27–30.
  150. Jenkins DM, Newton WD. Atheroembolism. Am Surg. 1991; 57(9): 588–590.
  151. Kaufman J, Shah DM, Leather RP, et al. Atheroembolism and microthromboembolic syndromes: blue toe syndrome and disseminated atheroembolism. In: RB Rutherford, ed. Vascular Surgery, 4th ed. Philadelphia: WB Saunders. ; 1995: 669–677.
  152. McFarland RJ, Taylor RS, Woodyer AB, et al. The femoropopliteal segment as a source of peripheral atheroembolism. J Cardiovasc Surg (Torino). 1989; 30(4): 597–603.
  153. O'Keeffe ST, Woods BO, Breslin DJ, et al. Blue toe syndrome. Causes and management. Arch Intern Med. 1992; 152(11): 2197–2202.
  154. Preston FE, Emmanuel IG, Winfield DA, et al. Essential thrombocythaemia and peripheral gangrene. Br Med J. 1974; 3(5930): 548–552.
  155. Sharma PV, Babu SC, Shah PM, et al. Changing patterns of atheroembolism. Cardiovasc Surg. 1996; 4(5): 573–579.
  156. Wingo JP, Nix ML, Greenfield LJ, et al. The blue toe syndrome: hemodynamics and therapeutic correlates of outcome. J Vasc Surg. 1986; 3(3): 475–480.
  157. Brewer ML, Kinnison ML, Perler BA, et al. Blue toe syndrome: treatment with anticoagulants and delayed percutaneous transluminal angioplasty. Radiology. 1988; 166(1 Pt 1): 31–36.
  158. Clugston RA, Eisenhauer AC, Matthews RV. Atherectomy of the distal aorta using a “kissing-balloon” technique for the treatment of blue toe syndrome. AJR Am J Roentgenol. 1992; 159(1): 125–127.
  159. Dolmatch BL, Rholl KS, Moskowitz LB, et al. Blue toe syndrome: treatment with percutaneous atherectomy. Radiology. 1989; 173(3): 799–804.
  160. el Ashmaoui A, Do DD, Triller J, et al. Angioplasty of the terminal aorta: follow-up of 20 patients treated by PTA or PTA with stents. Eur J Radiol. 1991; 13(2): 113–117.
  161. Kumpe DA, Zwerdlinger S, Griffin DJ. Blue digit syndrome: treatment with percutaneous transluminal angioplasty. Radiology. 1988; 166(1 Pt 1): 37–44.
  162. Benvegna S, Cassina I, Giuntini G, et al. Atherothrombotic microembolism of the lower extremities (the blue toe syndrome) from atherosclerotic non-aneurysmal aortic plaques. J Cardiovasc Surg (Torino). 1990; 31(1): 87–91.
  163. Brenowitz JB, Gregory J, Edwards WS. Diagnosis and treatment of peripheral atheromatous emboli. J Cardiovasc Surg (Torino). 1978; 19(5): 499–502.
  164. Bruns FJ, Segel DP, Adler S. Control of cholesterol embolization by discontinuation of anticoagulant therapy. Am J Med Sci. 1978; 275(1): 105–108.
  165. FEDER W, AUERBACH R. Ann Intern Med. 1961; 55: 911–917.
  166. MOLDVEEN-GERONIMUS M, MERRIAM JC. Cholesterol Embolization: From Pathological Curiosity to Clinical Entity. Circulation. 1967; 35(5): 946–953.
  167. ROBERTS B, ROSATO FE, ROSATO EF. HEPARIN--A CAUSE OF ARTERIAL EMBOLI? Surgery. 1964; 55: 803–808.
  168. WEISMANN RE, TOBIN RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958; 76(2): 219–25; discussion 225.
  169. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997; 204(1): 87–96.
  170. Kvilekval KH, Yunis JP, Mason RA, et al. After the blue toe: prognosis of noncardiac arterial embolization in the lower extremities. J Vasc Surg. 1993; 17(2): 328–34; discussion 334.
  171. Murphy KD, Encarnacion CE, Le VA, et al. Iliac artery stent placement with the Palmaz stent: follow-up study. J Vasc Interv Radiol. 1995; 6(3): 321–329.
  172. Matchett WJ, McFarland DR, Eidt JF, et al. Blue toe syndrome: treatment with intra-arterial stents and review of therapies. J Vasc Interv Radiol. 2000; 11(5): 585–592.
  173. Naylor AR, Mehta Z, Rothwell PM, et al. Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg. 2002; 23(4): 283–294.
  174. Paraskevas KI, Nduwayo S, Saratzis A, et al. Synchronous/ staged carotid stenting and coronary bypass surgery: an updated systematic re- view and meta-analysis. Eur J Vasc Endovasc Surg. 2017; 53: 309–319.
  175. Aboyans V, Lacroix P. Indications for carotid screening in patients with coronary artery disease. Presse Med. 2009; 38(6): 977–986.
  176. Steinvil A, Sadeh B, Arbel Y, et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll Cardiol. 2011; 57(7): 779–783.
  177. Sirimarco G, Amarenco P, Labreuche J, et al. Carotid Atherosclerosis and Risk of Subsequent Coronary Event in Outpatients With Atherothrombosis. Stroke. 2013; 44(2): 373–379.
  178. Cohen MG, Pascua JA, Garcia-Ben M, et al. A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J. 2005; 150(6): 1204–1211.
  179. Aboyans V, Tanguy B, Desormais I, et al. Prevalence of renal artery disease and its prognostic significance in patients undergoing coronary bypass grafting. Am J Cardiol. 2014; 114(7): 1029–1034.
  180. Lee Y, Shin JH, Park HC, et al. A prediction model for renal artery stenosis using carotid ultrasonography measurements in patients undergoing coronary angiography. BMC Nephrol. 2014; 15: 60.
  181. Conlon PJ, Little MA, Pieper K, et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001; 60(4): 1490–1497.
  182. Ahmed B, Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg. 2009; 37(3): 262–271.
  183. Aboyans V. Polyvascular disease: definition, epidemiology, relevance. In: P Lanzer, ed. PanVascular Medicine. Springer. 2015: 4779–4810.
  184. Aboyans V, Desormais I, Magne J, et al. Renal Artery Stenosis in Patients with Peripheral Artery Disease: Prevalence, Risk Factors and Long-term Prognosis. Eur J Vasc Endovasc Surg. 2017; 53(3): 380–385.
  185. Amighi J, Schlager O, Haumer M, et al. Renal artery stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral artery disease. Eur J Clin Invest. 2009; 39(9): 784–792.
  186. Kelly R, Staines A, MacWalter R, et al. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol. 2002; 39(2): 219–224.
  187. Ward RP, Goonewardena SN, Lammertin G, et al. Comparison of the frequency of abnormal cardiac findings by echocardiography in patients with and without peripheral arterial disease. Am J Cardiol. 2007; 99(4): 499–503.
  188. Hedberg P, Hammar C, Selmeryd J, et al. Left ventricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease. Eur J Heart Fail. 2014; 16(6): 625–632.
  189. Rizvi S, Kamran H, Salciccioli L, et al. Relation of the ankle brachial index to left ventricular ejection fraction. Am J Cardiol. 2010; 105(1): 129–132.
  190. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999; 19(3): 538–545.
  191. Aronow WS, Ahmed MI, Ekundayo OJ, et al. A propensity-matched study of the association of peripheral arterial disease with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009; 103(1): 130–135.
  192. Ostergren J, Sleight P, Dagenais G, et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004; 25(1): 17–24.
  193. Gupta DK, Skali H, Claggett B, et al. Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). JACC Heart Fail. 2014; 2(5): 447–454.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl